Management of ovarian cancer risk in women with BRCA1/2 pathogenic variants

CMAJ. 2019 Aug 12;191(32):E886-E893. doi: 10.1503/cmaj.190281.

Authors

Melissa Walker¹, Michelle Jacobson², Mara Sobel²

Affiliations

¹ Department of Obstetrics and Gynaecology (Walker), University of Toronto; Department of Obstetrics & Gynaecology (Walker, Jacobson, Sobel), Women's College Hospital; Department of Obstetrics & Gynaecology (Jacobson, Sobel), Sinai Health System, Toronto, Ont. Melissa.Walker@mail.utoronto.ca.
² Department of Obstetrics and Gynaecology (Walker), University of Toronto; Department of Obstetrics & Gynaecology (Walker, Jacobson, Sobel), Women's College Hospital; Department of Obstetrics & Gynaecology (Jacobson, Sobel), Sinai Health System, Toronto, Ont.

No abstract available

Publication types

Review

MeSH terms

Age Factors
CA-125 Antigen / metabolism
Contraceptives, Oral, Hormonal / therapeutic use*
Early Detection of Cancer
Estrogen Replacement Therapy / methods*
Female
Genes, BRCA1
Genes, BRCA2
Genetic Counseling
Genetic Testing
Hereditary Breast and Ovarian Cancer Syndrome / diagnosis
Hereditary Breast and Ovarian Cancer Syndrome / genetics
Hereditary Breast and Ovarian Cancer Syndrome / therapy*
Humans
Hysterectomy
Menopause, Premature
Ovarian Neoplasms / diagnosis
Ovarian Neoplasms / mortality
Ovarian Neoplasms / pathology
Ovarian Neoplasms / prevention & control*
Prophylactic Surgical Procedures / methods*
Salpingo-oophorectomy / methods*
Ultrasonography

Substances

CA-125 Antigen
Contraceptives, Oral, Hormonal